Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Tuesday, 10 September 2019

SCENESSE® presented at ICPP in Milan

  CLINUVEL PHARMACEUTICALS LTD today announced that safety and effectiveness data from the treatment of erythropoietic protoporphyria (EPP) patients with SCENESSE® (afamelanotide 16mg), will be presented this week at the International Congress on Porphyrins and Porphyrias (ICPP) in Milan, Italy. […] Download PDF

Download PDF
 
 
Tuesday, 03 September 2019

Appendix 3Y

  Change of Director’s Interest Notice Appendix 3Y    

Download PDF
 
 

  Download Notification of Dividend/Distribution

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Clarifies ex-Dividend Date

  In relation to the dividend announcement earlier today, CLINUVEL PHARMACEUTICALS LTD clarifies the ex-dividend date is to be 04 September 2019. Download PDF

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Declares Final Dividend

  CLINUVEL PHARMACEUTICALS LTD is pleased to announce that it will issue a dividend for the financial year ended 30 June 2019. This is the second final dividend in its corporate history. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD (CLINUVEL), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4E and Preliminary Financial Report for the year ending 30 June 2019. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that its program in systemic photoprotection will be discussed and presented at the first European-American meeting of the International Congress on Photobiology and Congress of the European Society for Photobiology, Light and Life, held in Barcelona, Spain, from 25-30 August. […] Download PDF

Download PDF
 
 
Tuesday, 20 August 2019

CLINUVEL Newsletter – August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. […] Download PDF

Download PDF
 
 
Wednesday, 31 July 2019

Appendix 4C

  CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.   Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that non-executive Director, Willem Blijdorp has replaced Managing Director and Chief Executive Officer, Dr Philippe Wolgen as a member of the Audit & Risk Committee. […] Download PDF

Download PDF
 
 
Thursday, 11 July 2019

CLINUVEL Newsletter – July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for SCENESSE® (afamelanotide 16mg) by three months […] Download PDF

Download PDF
 
 

   21 June 2019      Download PDF

Download PDF
 
 

CLINUVEL INCLUDED IN S&P/ASX 200 INDEX 14 June 2019 Download PDF    

Download PDF
 
 

6 June 2019   Download PDF

Download PDF
 
 

Melbourne, Australia 5 June 2019 Download PDF

Download PDF
 
Monday, 05 November 2018

CLINUVEL Newsletter - November 2018

05 November 2018 The most recent quarterly financial results (1 July-30 September 2018) confirm the steady growth in clinical demand for SCENESSE® (afamelanotide 16mg) in erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder.1 EPP is classified …

Download PDF
 
Friday, 05 October 2018

Chair Letter to Shareholders

05 October 2018 This is a thank you to shareholders, investors, patients, clinicians, and all those who have continued to support CLINUVEL together with new shareholders who have recently gained confidence to join the CLINUVEL register. …

Download PDF
 
Friday, 27 July 2018

CLINUVEL Newsletter - July 2018

27 July 2018 On 25 June 2018 CLINUVEL announced its New Drug Application (NDA) for SCENESSE® (afamelanotide 16mg) for adult erythropoietic protoporphyria (EPP) patients had been submitted to the US Food and Drug Administration (FDA). It …

Download PDF
 
Monday, 26 March 2018

CLINUVEL Newsletter - March 2018

26 March 2018 The erythropoietic protoporphyria (EPP) Expert Meeting in Vienna on 16 March has had quite an impact on our global teams working in the fields of photomedicine and melanocortins. The interest in SCENESSE® (afamelanotide …

Download PDF
 
Monday, 12 February 2018

CLINUVEL Newsletter - February 2018

12 February 2018 We started this year with limitless optimism and energy, and I attribute this to a foundation of internal changes made over the past 16 months. Our fascinating journey is marred with frequent need …

Download PDF
 
Wednesday, 10 January 2018

Chair Letter to Shareholders

11 January 2018 Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead. The Group will engage in many activities on several continents, and we …

Download PDF
 
Thursday, 07 December 2017

CLINUVEL Newsletter - December 2017

07 December 2017 The CLINUVEL team is looking with much optimism and energy to the start of 2018. I believe the year ahead is one where the Company will make great strides on various fronts: research, …

Download PDF